In an article coming out today in the New England Journal of Medicine (article abstract), researchers from the University of Pennsylvania School of Medicine and the National Institutes of Health Reproductive Medicine research network report their findings from a study comparing the pregnancy and live birth rates in women with PCOS using clomiphene (clomid), metformin and a combination of both.
Christos Coutifaris, MD, PhD, Director of the Division of Reproductive Endocrinology and Infertility and the principal investigator from Penn. is quoted as having said that he recommends and supports the use of clomiphene alone and not combined with Metformin as a first-line therapy for infertility in women with PCOS.
The study included 626 infertile women with PCOS who were divided into three groups. The first group received clomiphene and a placebo. The second received metformin and a placebo, and the third group received both metformin and clomiphene. The women took the medication for up to six months.
- In the metformin only group, 15 out of 208 women had given birth (7.2%).
- In the clomiphene only group, 47 out of 209 women had given birth (22.5%).
- In the combined clomiphene-metformin group, 56 out of 209 women had given birth (26.8%).
The researchers also found that, compared to the other women in the study, obese women were less likely to conceive during the course of the study and less likely to ovulate in response to metformin.